info@boneforte.com
Did you know that about 50% of fragility fractures occur in people with normal or near-normal BMD? REMS offers a new way to determine fracture risk through the Fragility Score, which quantifies bone quality.
Talk to your healthcare provider about REMS and whether it might be a good option for assessing and monitoring your bone health. Remember, you are in charge of your healthcare decisions, and your provider is there to offer guidance and support.
REMS has been used in the European Union and several other countries for nearly a decade, including Italy, Belgium, France, United Kingdom, Poland, Australia, Japan, India, Brazil, Canada, and Spain. In 2020, REMS was designated the official method for bone densitometry in Italy.
In the United States, REMS received FDA approval in 2018 for the diagnosis and monitoring of osteoporosis, as well as for providing FRAX-based fracture risk assessments. As more healthcare providers become aware of the benefits of REMS, its adoption is expected to grow in the coming years.
If you're interested in REMS for your bone health assessment, it's essential to have an open and respectful conversation with your healthcare provider. Keep in mind that not all providers may be familiar with REMS technology, so be prepared to share information and discuss your concerns.
Some tips for talking to your provider about REMS:
Remember, your bone health is a crucial aspect of your overall well-being, and you have the right to advocate for the best possible care.
Office
All Rights Reserved | BoneForte